We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
<p>The World Health Organization (WHO) estimates that of the 35 million healthcare workers worldwide, at least 2 million people, suffer accidental needlestick injuries each year. More than 20 pathogens have been reportedly transmitted from needlesticks. The most serious transmissions include: Hepatitis B, Hepatitis C and HIV. Two of the most common causes of needlestick injuries are two-handed recapping and the unsafe collection and disposal of sharps. According to Occupational Safety and Health Administration (OSHA), nurses have the most frequent exposure, registering almost 50 percent of needlestick injuries. Hollow-bore needles are the main cause of injury in 68.5 percent of all cases. <sup>1</sup></p><p> </p>
West’s Graham Reynolds will present “An Integrated Approach to Biologic Drug Delivery Systems: Meeting the needs of the patient, and optimizing drug product performance,” at the Drug Delivery Partnerships meeting in Las Vegas, on January 25, 2012.
<span style="color: black;">West is <a href="https://www.youtube.com/watch?v=42PhOvTdfRg"><span style="color: #0000ff; text-decoration: underline;">on the road</span></a> again, traveling more than 1,000 miles from our Jersey Shore, PA, manufacturing facility—where we visited during our first installment of <a href="https://westpharma.wordpress.com/2015/06/01/west-kicks-off-west-on-the-road/"><span style="color: #0000ff; text-decoration: underline;">West On The Road</span></a> —to the sunshine state, where we’ll be touring our state-of-the-art Clearwater plant.</span>
Demonstrating the compatibility of any material in contact with drug product throughout its lifecycle (manufacture, containment, and delivery) is a necessity for a regulatory submission. Defined as extractables and leachables, these assessments continue to evolve and expand due to consistently increasing regulatory agency expectations. Agency expectations require you to act sooner rather than later. Waiting until Phase III in drug development can lead to delays and additional costs due to poor assessments that are questioned by the reviewer, or incomplete submissions that require you to redo or execute additional work. You can start your Extractables and Leachables (E&L) assessment as soon as you have selected your packaging components.
We are pleased to announce that Jennifer Ogden, Director, Global Accounts, has been recognized by the HealthCare Businesswomen’s Association (HBA) as West’s 2015 Rising Star. Jenn is a leader among the sales force and is responsible for developing and driving the execution of account strategies with West’s global biotech customers.
English
Chinese
